CD274 and non-small cell lung carcinoma: The diagnostic and therapeutic guidelines consider immunochemotherapy to be the first-line treatment of choice in advanced NSCLC; however, in many patients, this type of treatment is not feasible (e.g., when there is no adequate material available to assess the PD-L1 expression) [10,11].